http://orcid.org/0000-0003-3448-5555
Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Nana Luo, Qiuyue Wang, Min Lei, Zhiyong Li, Tianhao Li & Pingsheng Hao. (2022) Burning and Scaling Probably Associated with Dupilumab Therapy: A Case Report. Clinical, Cosmetic and Investigational Dermatology 15, pages 1659-1662.
Read now
Read now
Wojciech Francuzik, Aikaterina Alexiou & Margitta Worm. (2021) Safety of dupilumab in patients with atopic dermatitis: expert opinion. Expert Opinion on Drug Safety 20:9, pages 997-1004.
Read now
Read now
Articles from other publishers (31)
Juliane Haertlé, Petra Kienlin, Gabriele Begemann, Thomas Werfel & Lennart M. Roesner. (2023) Inhibition of IL-17 ameliorates keratinocyte-borne cytokine responses in an in vitro model for house-dust-mite triggered atopic dermatitis. Scientific Reports 13:1.
Crossref
Crossref
Alexandre Docampo-Simón, María J. Sánchez-PujolMaria A. Pastor-NietoAna Giménez-ArnauMercedes Rodríguez-SernaEsther Serra-BaldrichJavier MiquelJavier Sánchez-PérezTatiana Sanz-SánchezVioleta Zaragoza-NinetPaloma Sánchez-Pedreño, Jose M. CarrascosaMaria E. Gatica-OrtegaVirginia Fernández-RedondoSusana Córdoba-GuijarroRicardo González-PérezJuan F. Silvestre. (2023) Patch Testing in Patients With Severe Atopic Dermatitis Treated With Dupilumab: A Multicentric Approach in Spain. Dermatitis® 34:4, pages 315-322.
Crossref
Crossref
Jun-Hong Tsai & Tsen-Fang Tsai. (2023) A Review of Dupilumab-Induced Adverse Events to Dermatologists and the Potential Pathogenesis in the Treatment of Atopic Dermatitis. Dermatitis®.
Crossref
Crossref
Jundong Kim & Kyuseok Kim. (2023) Elucidating the potential pharmaceutical mechanism of Gyejibokryeong-hwan on rosacea using network analysis. Medicine 102:9, pages e33023.
Crossref
Crossref
Jiahua Li, Erdong Wei, Amin Reisinger, Lars Einar French, Benjamin M. Clanner-Engelshofen & Markus Reinholz. (2023) Comparison of Different Anti-Demodex Strategies: A Systematic Review and Meta-Analysis. Dermatology 239:1, pages 12-31.
Crossref
Crossref
Andrea N. Sitek, James T. Li & Thanai Pongdee. (2023) Risks and safety of biologics: A practical guide for allergists. World Allergy Organization Journal 16:1, pages 100737.
Crossref
Crossref
Fengming Jia, Qing Zhao, Peidian Shi, Hong Liu & Furen Zhang. (2022)
Dupilumab: Advances in the off‐label usage of
IL4
/
IL13
antagonist in dermatoses
. Dermatologic Therapy 35:12.
Crossref
Crossref
J. Ahn, D.H. Lee, C.H. Na, D.H. Shim, Y.S. Choi, H.J. Jung & E.L. Simpson. (2022) Facial erythema in patients with atopic dermatitis treated with Dupilumab – a descriptive study of morphology and Aetiology. Journal of the European Academy of Dermatology and Venereology 36:11, pages 2140-2152.
Crossref
Crossref
Roberto R. Ricardo-Gonzalez, Maya E. Kotas, Claire E. O’Leary, Katelyn Singh, William Damsky, Chang Liao, Elizabeth Arouge, Iliana Tenvooren, Diana M. Marquez, Andrew W. Schroeder, Jarish N. Cohen, Marlys S. Fassett, Jinwoo Lee, Scott G. Daniel, Kyle Bittinger, Roberto Efraín Díaz, James S. Fraser, Niwa Ali, K. Mark Ansel, Matthew H. Spitzer, Hong-Erh Liang & Richard M. Locksley. (2022) Innate type 2 immunity controls hair follicle commensalism by Demodex mites. Immunity 55:10, pages 1891-1908.e12.
Crossref
Crossref
Jacob P. Thyssen, Lea K. Nymand, Julia‐Tatjana Maul, Peter Schmid‐Grendelmeier, Jashin J. Wu, Simon Francis Thomsen & Alexander Egeberg. (2022) Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study. Journal of the European Academy of Dermatology and Venereology 36:6, pages 890-896.
Crossref
Crossref
Ya-Chu Tsai & Tsen-Fang Tsai. (2022) Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes. International Journal of Molecular Sciences 23:10, pages 5518.
Crossref
Crossref
Mari Okune, Naoko Okiyama, Maki Fukuzono, Katsuhito Sasaki & Toshifumi Nomura. (2022) Development of systemic lupus erythematosus after dupilumab treatment in a case of atopic dermatitis. The Journal of Dermatology 49:5, pages 556-559.
Crossref
Crossref
Michael J. Murphy, Jeffrey M. Cohen, Matthew D. Vesely & William Damsky. (2022) Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. Journal of the American Academy of Dermatology 86:5, pages 1080-1091.
Crossref
Crossref
Ellen Q. Wang, Vu Le, Jennifer A. Winton, Sakambari Tripathy, Sangeeta Raje, Lisy Wang, Martin E. Dowty & Bimal K. Malhotra. (2022) Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites. The Journal of Clinical Pharmacology 62:4, pages 505-519.
Crossref
Crossref
Hideaki Uchida, Masahiro Kamata, Shota Egawa, Mayumi Nagata, Saki Fukaya, Kotaro Hayashi, Atsuko Fukuyasu, Takamitsu Tanaka, Takeko Ishikawa, Takamitsu Ohnishi & Yayoi Tada. (2021) Effectiveness of tacrolimus ointment on facial lesions refractory to topical corticosteroid in patients with atopic dermatitis receiving dupilumab. Journal of Cutaneous Immunology and Allergy 5:1, pages 17-21.
Crossref
Crossref
Young Jae Kim, Mi Young Lee & Chong Hyun Won. (2022) Acral erythema arising in patients with atopic dermatitis after dupilumab therapy: A case report of 3 patients. Asia Pacific Allergy 12:1.
Crossref
Crossref
Alyssa G. Ashbaugh, Emi M. Murase, Jodie Raffi, Nina Botto & Jenny E. Murase. (2022) Characterization of Residual Facial Dermatitis during Dupilumab Therapy: A Retrospective Chart Review to Delineate the Potential Role of Expanded Series Patch Testing. Dermatitis 33:1, pages 51-61.
Crossref
Crossref
Sonal Muzumdar, Lauren Skudalski, Kelley Sharp & Reid A. Waldman. (2021) Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians. American Journal of Clinical Dermatology 23:1, pages 61-67.
Crossref
Crossref
Masako Matsutani, Yasutomo Imai, Yukako Inoue, Minori Nakatani‐Kusakabe, Masaru Natsuaki, Kiyofumi Yamanishi & Nobuo Kanazawa. (2021) Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real‐world clinical practice. The Journal of Dermatology 48:10, pages 1564-1568.
Crossref
Crossref
Masahiro Kamata & Yayoi Tada. (2021) A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis. JID Innovations 1:3, pages 100042.
Crossref
Crossref
Daphne S. Bakker, Maria M. van der Wal, Lukas E.M. Heeb, Barbara Giovannone, Mindy Asamoah, Eveline M. Delemarre, Julia Drylewicz, Stefan Nierkens, Onur Boyman, Marjolein S. de Bruin-Weller, Judith L. Thijs & Femke van Wijk. (2021) Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis. Journal of Investigative Dermatology 141:8, pages 1943-1953.e13.
Crossref
Crossref
Tae-Eun Kim & Min Kyung Shin. (2021) De novo case of lichenoid eruption following dupilumab treatment. JAAD Case Reports 13, pages 71-72.
Crossref
Crossref
Andrew C. Krakowski, Stephen C. Senft & Warren R. Heymann. (2021) Demodex Folliculitis and Recent Dupilumab Administration. Pediatrics 147:5.
Crossref
Crossref
S. Hamich, J. Rakotoson, M. Sanchez & B. Lagrange. (2021) Réaction paradoxale eczématiforme liée au dupilumab. Annales de Dermatologie et de Vénéréologie - FMC 1:4, pages 229-231.
Crossref
Crossref
Christina E. Bax, Michele C. Khurana, James R. Treat, Leslie Castelo‐Soccio, Adam I. Rubin & Patrick J. McMahon. (2021) New‐onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis. Pediatric Dermatology 38:2, pages 390-394.
Crossref
Crossref
N. Okiyama, Y. Nakamura, Y. Ishitsuka, S. Inoue, N. Kubota, A. Saito, R. Watanabe, Y. Fujisawa & K. Igawa. (2020) Successful topical treatment with ketoconazole for facial rashes refractory to dupilumab in patients with atopic dermatitis: case reports. Journal of the European Academy of Dermatology and Venereology 34:9.
Crossref
Crossref
Tatjana Honstein & Thomas Werfel. (2020) The show must go on: an update on clinical experiences and clinical studies on novel pharmaceutical developments for the treatment of atopic dermatitis. Current Opinion in Allergy & Clinical Immunology 20:4, pages 386-394.
Crossref
Crossref
Ali Al‐Janabi & Alexander M. Marsland. (2020) Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports. Clinical Case Reports 8:8, pages 1458-1460.
Crossref
Crossref
Tamara Quint, Patrick M. Brunner, Christoph Sinz, Irene Steiner, Robin Ristl, Kornelia Vigl, Susanne Kimeswenger, Katharina Neubauer, Detlev Pirkhammer, Martin Zikeli, Wolfram Hoetzenecker, Norbert Reider & Christine Bangert. (2020) Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis. Journal of Clinical Medicine 9:4, pages 1241.
Crossref
Crossref
Yu-Kuei Lee, Sheau-Chiou Chao, Chaw-Ning Lee & Jia-Horung Hung. (2019) Scleritis and anterior uveitis may herald the development of an epibulbar tumor in patients with extranodal Rosai-Dorfman disease: a case report. BMC Ophthalmology 19:1.
Crossref
Crossref
Roberto Ricardo-Gonzalez, Maya E. Kotas, Claire E. O'Leary, Iliana Tenvooren, Diana M. Marquez, Katelyn Singh, William Damsky, Andrew W. Schroeder, Jarish N. Cohen, Marlys Fassett, Jinwoo Lee, Scott G. Daniel, Kyle Bittinger, Roberto Efraín Díaz, James S. Fraser, Mark Ansel, Matthew Spitzer, Hong-Erh Liang & Richard M. Locksley. (2022) Innate Type 2 Immunity Controls Hair Follicle Commensalism by <i>Demodex</i> Mites. SSRN Electronic Journal.
Crossref
Crossref